Mode
Text Size
Log in / Sign up
Phase 4 Completed N=87 Randomized Quadruple-blind Treatment

Efficacy of Fish Oil in Lupus Patients

Source: ClinicalTrials.gov NCT00828178 ↗
Enrolled (actual)
87
Serious AEs
0.0%
Results posted
Nov 2016
Primary outcomePrimary: Effect on Brachial Artery Flow Dilation by Omega-3 Versus Placebo. — 0.32; 0.33; 0.32; 0.33 cm — p=0.87
◆ Published Evidence
Highly cited
1,827citations · ~63 / year
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study.
American journal of epidemiology · 1997 · High-confidence link

Summary

The investigators hypothesize that low-dose dietary supplementation with omega-3 fish oil will improve disease activity and endothelial function in Systemic Lupus Erythematosus (SLE) patients.

Linked Publications (2)

  • Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study.
    American journal of epidemiology · 1997 · 1,827 citations · High-confidence link
  • The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus.
    The Journal of rheumatology · 2004 · 115 citations · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Effect on Brachial Artery Flow Dilation by Omega-3 Versus Placebo.
0.32; 0.33; 0.32; 0.33 0.87
SECONDARY
Effect of Omega-3 Versus Placebo on Disease Activity in SLE.
1.5; 1.5; 0.49; 0.41 0.1801
SECONDARY
Effect on Markers of Inflammation: ICAM and VCAM by Omega-3 Versus Placebo.
-1.61; -5.56; -17.52; 26.57

Eligibility Criteria

Inclusion Criteria

  • Patients with a clinical diagnosis of SLE are eligible.
  • Patients must be 18 years of age or older and able to give informed consent.

Exclusion Criteria

  • SLE patients who are allergic to fish oil or any omega 3 product.
  • Patients who are pregnant or are planning to become pregnant or are nursing.
  • Omega-3 use within the previous 6 weeks of enrollment.
  • Use of warfarin or heparin.
  • Patients who have coronary artery disease.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00828178) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search